| Literature DB >> 30873747 |
Abbas Yadegar1, Ashraf Mohabati Mobarez2, Mohammad Reza Zali3.
Abstract
Genetic variability in cagL gene especially within the Helicobacter pylori CagL hypervariable motif (CagLHM) may affect the development of gastric cancer. Therefore, this study was conducted to investigate the association of CagL diversity with clinical outcomes and with H pylori virulence markers. A total of 126 patients with different gastric diseases including non-ulcer dyspepsia (NUD), peptic ulcer disease (PUD), gastric erosion (GE), and gastric cancer (GC) were enrolled. H pylori was cultured from gastric biopsies, and the isolates were screened for the presence of cagL, cagA, vacA, babA2, sabA, and cagPAI integrity by PCR. The amino acid polymorphisms of cagL were analyzed using DNA sequencing. We isolated 61 (48.4%) H pylori strains from 36 NUD, eight PUD, 12 GE, and five GC patients. Almost all isolates were cagL positive (97%), and their RGD, RHS, and SKIIVK motifs were highly conserved. Among 10 CagLHM variants identified, NEIGQ and NKIGQ were detected as the most prevalent sequences. Interestingly, a significant association was found between the presence of NKMGK and PUD (P = 0.002). Notably, the NEIGQ isolates with multiple C-type EPIYA repeat that carried intact cagPAI correlated with disease risk for PUD, GE, and GC (P = 0.021). In conclusion, we identified novel variants of H pylori CagLHM sequences in Iranian population such as NKMGK, which was associated with disease risk for PUD. Further studies using a large number of strains are required to better clarify the function of certain CagLHM motifs in gastric carcinogenesis and disease outcome.Entities:
Keywords: zzm321990Helicobacter pylorizzm321990; zzm321990cagLzzm321990; CagLHM; Iran; disease outcome; diversity; virulence factors
Mesh:
Substances:
Year: 2019 PMID: 30873747 PMCID: PMC6488209 DOI: 10.1002/cam4.1941
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Distribution of 46 H pylori cagL‐positive isolates in relation to clinical status and demographic data of the respective patients
| No. | Strain | GenBank Accession No. | Clinical status | Gender (F/M) | Age (years) | Ethnicity |
|---|---|---|---|---|---|---|
| 1 | HpOC179 |
| GC | F | 63 | Fars |
| 2 | HpNOC293 |
| GC | F | 52 | Turk |
| 3 | HpNOC560 |
| GC | F | 54 | Fars |
| 4 | HpOC485 |
| NUD | M | 54 | Fars |
| 5 | HpOC494 |
| NUD | F | 42 | Fars |
| 6 | HpOC557 |
| PUD | F | 50 | Fars |
| 7 | HpOC571 |
| NUD | F | 49 | Fars |
| 8 | HpOC573 |
| NUD | F | 36 | Turk |
| 9 | HpOC576 |
| NUD | F | 42 | Fars |
| 10 | HpOC606 |
| GE | M | 60 | Fars |
| 11 | HpOC639 |
| GE | M | 25 | Lur |
| 12 | HpOC656 |
| GE | M | 41 | Turk |
| 13 | HpOC658 |
| NUD | F | 33 | Fars |
| 14 | HpOC723 |
| NUD | M | 47 | Turk |
| 15 | HpOC728 |
| NUD | F | 23 | Turk |
| 16 | HpOC734 |
| NUD | M | 50 | Fars |
| 17 | HpOC743 |
| NUD | M | 60 | Turk |
| 18 | HpOC751 |
| NUD | F | 44 | Fars |
| 19 | HpOC770 |
| NUD | F | 73 | Fars |
| 20 | HpOC775 |
| GE | F | 39 | Fars |
| 21 | HpOC785 |
| NUD | M | 60 | Turk |
| 22 | HpOC790 |
| NUD | M | 26 | Fars |
| 23 | HpOC793 |
| NUD | F | 41 | Fars |
| 24 | HpOC796 |
| GE | F | 51 | Fars |
| 25 | HpOC797 |
| NUD | F | 28 | Fars |
| 26 | HpOC803 |
| NUD | M | 52 | Fars |
| 27 | HpOC805 |
| NUD | F | 48 | Fars |
| 28 | HpOC808 |
| NUD | F | 65 | Lur |
| 29 | HpOC810 |
| NUD | F | 53 | Lur |
| 30 | HpOC814 |
| PUD | F | 25 | Lur |
| 31 | HpOC815 |
| NUD | F | 34 | Fars |
| 32 | HpOC816 |
| NUD | M | 14 | Fars |
| 33 | HpOC819 |
| GE | F | 32 | Turk |
| 34 | HpOC824 |
| PUD | F | 43 | Turk |
| 35 | HpOC852 |
| NUD | M | 45 | Fars |
| 36 | HpOC854 |
| NUD | F | 71 | Fars |
| 37 | HpOC897 |
| PUD | F | 60 | Fars |
| 38 | HpOC912 |
| PUD | F | 64 | Fars |
| 39 | HpOC913 |
| PUD | M | 40 | Fars |
| 40 | HpOC937 |
| NUD | F | 48 | Fars |
| 41 | HpOC939 |
| PUD | M | 54 | Turk |
| 42 | HpOC975 |
| GE | F | 31 | Fars |
| 43 | HpOC996 |
| GE | F | 52 | Fars |
| 44 | HpOC1021 |
| GE | F | 50 | Fars |
| 45 | HpOC1028 |
| NUD | F | 27 | Turk |
| 46 | HpOC1031 |
| NUD | F | 52 | Fars |
GC, gastric cancer; GE, gastric erosion; NUD, non‐ulcer dyspepsia; PUD, peptic ulcer disease.
The accession numbers are deposited in GenBank database for cagL gene sequences of the H pylori strains in this study.
Distribution of amino acid and nucleotide substitutions in CagL of 46 H pylori isolates from patients with different gastric diseases
| CagL polymorphic residue | Amino acid diversity | Number of disease state‐associated | |||
|---|---|---|---|---|---|
|
NUD |
PUD |
GE |
GC | ||
| 41 | V/T/A | 21:3:3 | 5:2:0 | 9:0:0 | 1:1:1 |
| GT(G/ | GTG: | GT(G/ | GTG: | ||
| 56 | A/T | 24:3 | 7:0 | 9:0 | 3:0 |
| GCT: | GCT | GCT | GCT | ||
| 58 | D/N | 3:24 | 2:5 | 2:7 | 0:3 |
| GAT: | GAT: | GAT: |
| ||
| 59 | K/E | 14:13 | 4:3 | 4:5 | 1:2 |
| AAA: | AAA: | AAA: | AAA: | ||
| 60 | M/I | 3:24 | 3:4 | 2:7 | 0:3 |
| ATG:AT | ATG:AT | ATG:AT | AT | ||
| 61 | G/S | 25:2 | 7:0 | 9:0 | 3:0 |
| GGT: | GGT | GGT | GGT | ||
| 62 | E/Q/K | 1:26:0 | 0:3:4 | 0:9:0 | 0:3:0 |
| GAA: |
|
|
| ||
| 65 | A/T | 26:1 | 6:1 | 9:0 | 3:0 |
| GCT: | GCT: | GCT | GCT | ||
| 69 | K/E | 27:0 | 6:1 | 9:0 | 3:0 |
| AAA | AAA: | AAA | AAA | ||
| 72 | A/T | 27:0 | 7:0 | 9:0 | 2:1 |
| GCC | GCC | GCC | GCC: | ||
| 114 | I/M | 0:27 | 0:7 | 0:9 | 0:3 |
| AT | AT | AT | AT | ||
| 118 | P/L | 26:1 | 7:0 | 9:0 | 3:0 |
| CCC:C | CCC | CCC | CCC | ||
| 122 | K/N | 10:17 | 1:6 | 2:7 | 1:2 |
| AAG:AA( | AAG:AA( | AA(G/ | AAG:AA( | ||
| 134 | I/V | 9:18 | 1:6 | 3:6 | 1:2 |
| ATT: | ATT: | ATT: | ATT: | ||
| 171 | A/S | 26:1 | 7:0 | 8:1 | 3:0 |
| GCT: | GCT | GCT: | GCT | ||
| 175 | T/I | 27:0 | 7:0 | 8:1 | 3:0 |
| ACT | ACT | ACT:A | ACT | ||
| 194 | R/K | 23:4 | 7:0 | 8:1 | 3:0 |
| AGA:A | AGA | AGA:A | AGA | ||
| 200 | Q/H | 1:26 | 0:7 | 1:8 | 0:3 |
| CAA:CA | CA | CAA:CA | CA | ||
| 210 | E/K | 26:1 | 7:0 | 9:0 | 3:0 |
| GAG: | GAG | GAG | GAG | ||
| 216 | R/I | 26:1 | 6:1 | 9:0 | 3:0 |
| AGA:A | AGA:A | AGA | AGA | ||
GC, gastric cancer; GE, gastric erosion; NUD, non‐ulcer dyspepsia; PUD, peptic ulcer disease.
Positions of amino acid residues correspond to the H pylori P12 reference strain.
Codon usage in italics; bolded nucleotides represent nucleotide polymorphisms.
Denotes that all of our strains had M (ATG) residue in this position in comparison to H pylori P12 that had I (ATA).
Figure 1Partial amino acid sequence alignment of CagL from 46 H pylori clinical strains from patients with different gastric diseases. The CagL amino acid sequence of the H pylori reference strain P12 is shown on the top line. The clinical strains included 27 from non‐ulcer dyspepsia (NUD), seven from peptic ulcer disease (PUD), nine from gastric erosion (GE), and three from gastric cancer (GC) patients. Sequences of CagL hypervariable motif (CagLHM), conserved arginine‐glycine‐aspartate motifs (RGD), RGD helper sequence (RHS) motifs comprising the FEANE (Phe‐Glu‐Ala‐Asn‐Glu) sequence, and highly conserved C‐terminal hexapeptide motifs consisting of the SKIIVK (Ser‐Lys‐Ile‐Ile‐Val‐Lys) sequence are surrounded by boxes
Figure 2Phylogenetic tree of 46 H pylori clinical strains based on cagL nucleotide sequences. Neighbor‐joining tree of concatenated sequences was constructed using MEGA7 software with bootstrap method at 1000 replications. The evolutionary distances were computed using the Tamura 3‐parameter model
CagLHM sequence types and gastric disease associations of 46 H pylori isolates included in this study
| CagLHM sequence |
Total | Patient health status | |||
|---|---|---|---|---|---|
|
NUD |
PUD |
GE |
GC | ||
| NEIGQ | 21 | 13 | 1 | 5 | 2 |
| NKIGQ | 9 | 7 | — | 1 | 1 |
| DKIGQ | 4 | 2 | 1 | 1 | — |
| NKMGQ | 3 | 2 | — | 1 | — |
| NKMGK | 3 | — | 3 | — | — |
| NKISQ | 2 | 2 | — | — | — |
| NEIGK | 1 | — | 1 | — | — |
| DKMGE | 1 | 1 | — | — | — |
| DEIGQ | 1 | — | 1 | — | — |
| DKMGQ | 1 | — | — | 1 | — |
|
| 0.153 |
| 0.735 | 1.0 | |
CagLHM CagL hypervariable motif; GC, gastric cancer; GE, gastric erosion; NUD non‐ulcer dyspepsia; PUD peptic ulcer disease.
The “—” denotes none detected.
Denotes that these CagLHM sequence types are novel and uniquely identified in our H pylori strains in comparison to global strains.
P value indicates the significant difference between CagLHM diversity and different gastric diseases. The statistically significant relationships are calculated by two‐tailed Fisher's exact test and presented in bold.
Differences in polymorphisms of various CagLHM sequence types of 46 H pylori isolates in relation to virulence genotypes and cagPAI integrity
| Virulence genotypes | CagLHM sequence type polymorphism | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
NEIGQ |
NKIGQ |
DKIGQ |
NKMGQ |
NKMGK |
NKISQ |
NEIGK |
DKMGE |
DEIGQ |
DKMGQ |
Total | |
|
| 5 | 4 | 1 | 1 | 1 | — | — | — | 1 | 1 | 14 |
|
| 12 | 2 | 3 | 1 | 2 | 1 | 1 | — | — | — | 22 |
|
| 4 | 3 | — | 1 | — | 1 | — | 1 | — | — | 10 |
|
| 20 | 9 | 4 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 44 |
|
| 1 | — | — | — | — | 1 | — | — | — | — | 2 |
|
| 16 | 7 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 38 |
|
| 5 | 2 | 1 | — | — | — | — | — | — | — | 8 |
| EPIYA motifs | |||||||||||
| ABC | 14 | 7 | 3 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 35 |
| ABCC | 4 | 1 | 1 | — | — | — | — | — | — | — | 6 |
| ABCCC | 1 | — | — | — | — | — | — | — | — | — | 1 |
| Mixed type | 1 | — | — | 1 | — | — | — | — | — | — | 2 |
|
| 1 | 1 | — | — | — | — | — | — | — | — | 2 |
|
| |||||||||||
| Intact | 14 | 6 | 4 | 2 | 3 | 1 | — | 1 | 1 | 1 | 33 |
| Partial | 7 | 3 | — | 1 | — | 1 | 1 | — | — | — | 13 |
CagLHM, CagL hypervariable motif; GC, gastric cancer; GE, gastric erosion; NUD, non‐ulcer dyspepsia; PUD peptic ulcer disease.
The “—” denotes none detected.
Denotes multiple cagA EPIYA motifs of different sizes, indicating mixed infections.
Figure 3Phylogenetic tree of 46 H pylori clinical strains based on translated CagL amino acid sequences. Neighbor‐joining tree of concatenated sequences was constructed using MEGA7 software with bootstrap method at 1000 replications. The evolutionary distances were computed using the Poisson correction method